

**Press release**

**Synairgen plc**  
(‘Synairgen’ or the ‘Company’)

**Notice of Report and Accounts**

Southampton, UK – 9 April 2013: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company with a focus on viral defence of the lungs, announces that the Company's Report and Accounts for the year ended 31 December 2012 has been posted to shareholders. A copy of the report and accounts can be found on the Company's website: [www.synairgen.com](http://www.synairgen.com).

-Ends-

For further information, please contact:

**Synairgen plc**

Richard Marsden, Chief Executive Officer  
John Ward, Finance Director

**Tel: + 44 (0) 23 8051 2800**

**FinnCap**

Geoff Nash, Christopher Raggett (Corporate Finance)  
Stephen Norcross, Simon Starr (Corporate Broking)

**Tel: + 44 (0) 20 7220 0500**

**Newgate Threadneedle**

Graham Herring  
Josh Royston

**Tel: + 44 (0) 20 7653 9850**